Anh: Hoãn phiên tòa xem xét dẫn độ nhà sáng lập WikiLeaks sang Mỹ

Ngày 10/9, phiên tòa xem xét việc dẫn độ người sáng lập trang mạng WikiLeaks Julian Assange sang Mỹ diễn ra tại Anh đã phải hoãn lại, sau khi một trong các luật sư đại diện cho phía Mỹ có những triệu chứng của bệnh viêm đường hô hấp cấp COVID-19.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Hy vọng mới trong điều trị ung thư tuyến tụy

Hy vọng mới trong điều trị ung thư tuyến tụy

Thế giới
(Baothanhhoa.vn) - Một loại thuốc thử nghiệm có tên Daraxonrasib đang mở ra hy vọng mới trong điều trị ung thư tuyến tụy, sau khi kết quả nghiên cứu công bố trên tạp chí y khoa New England Journal of Medicine cho thấy thuốc có thể giúp kéo dài gấp đôi thời gian sống...
Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh